LA JOLLA, CA - May 19, 2014 - Chemists at The Scripps Research Institute (TSRI) have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials in cancer patients.
The new report, published this week by the international chemistry journal Angewandte Chemie, focuses on a compound called TIC10.
In the new study, the TSRI scientists show that TIC10's structure differs subtly from a version published by another group last year, and that the previous structure associated with TIC10 in fact describes a molecule that lacks TIC10's anticancer activity.
By contrast, the correct structure describes a molecule with potent anticancer effects in animals, representing a new family of biologically active structures that can now be explored for their possible therapeutic uses.
"This new structure should generate much interest in the cancer research community," said Kim D. Janda, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI.
TIC10 was first described in a paper in the journal Science Translational Medicine in early 2013. The authors identified the compound, within a library of thousands of molecules maintained by the National Cancer Institute (NCI), for its ability to boost cells' production of a powerful natural antitumor protein, TRAIL. (TIC10 means TRAIL-Inducing Compound #10.)
As a small molecule, TIC10 would be easier to deliver in a therapy than the TRAIL protein itself. The paper, which drew widespread media coverage, reported that TIC10 was orally active and dramatically shrank a variety of tumors in mice, including notoriously treatment-resistant glioblastomas.
Tumors can develop resistance to TRAIL, but Janda had been studying compounds that defeat this resistance. The news about TIC10 therefore got his attention. "I thought, 'They have this molecule for upregulating TRAIL, and we have these molecules that can overcome tumor cell TRAIL resistance--the combination could be important,'" he said.
The original publication on TIC10 included a figure showing its predicted structure. "I saw the figure and asked one of my postdocs, Jonathan Lockner, to make some," Janda said.
Although the other team had seemingly confirmed the predicted structure with a basic technique called mass spectrometry, no one had yet published a thorough characterization of the TIC10 molecule. "There were no nuclear magnetic resonance data or X-ray crystallography data, and there was definitely no procedure for the synthesis," Lockner said. "My background was chemistry, though, so I was able to find a way to synthesize it starting from simple compounds."
There was just one problem with Lockner's newly synthesized "TIC10." When tested, it failed to induce TRAIL expression in cells, even at high doses.
"Of course I was nervous," remembered Lockner. "As a chemist, you never want to make a mistake and give biologists the wrong material."
To try to verify they had the right material, Janda's team obtained a sample of TIC10 directly from the NCI. "When we got that sample and tested it, we saw that it had the expected TRAIL-upregulating effect," said Nicholas Jacob, a graduate student in the Janda Laboratory who, with Lockner, was a co-lead author of the new paper. "That prompted us to look more closely at the structures of these two compounds."
The two researchers spent months characterizing their own synthesized material and the NCI material, using an array of sophisticated structural analysis tools. With Assistant Professor Vladimir V. Kravchenko of the TSRI Department of Immunology and Microbial Science, Jacob also tested the two compounds' biological effects.
The team eventually concluded that the TIC10 compound from the NCI library does boost TRAIL production in cells and remains promising as the basis for anticancer therapies, but it does not have the structure that was originally published.
The Right Structure
The originally published structure has a core made of three carbon-nitrogen rings in a straight line and does not induce TRAIL activity. The correct, TRAIL-inducing structure differs subtly, with an end ring that sticks out at an angle. In chemists' parlance, the two compounds are constitutional isomers: a linear imidazolinopyrimidinone and an angular imidazolinopyrimidinone.
Ironically, Lockner found that the angular TRAIL-inducing structure was easier to synthesize than the one originally described.
Now, with the correct molecule in hand and a solid understanding of its structure and synthesis, Janda and his team are moving forward with their original plan to study TIC10 in combination with TRAIL-resistance-thwarting molecules as an anticancer therapy.
The therapeutic implications of TIC10 may even go beyond cancer. The angular core of the TRAIL-inducing molecule discovered by Janda's team turns out to be a novel type of a biologically active structure--or "pharmacophore"--from which chemists may now be able to build a new class of candidate drugs, possibly for a variety of ailments.
"One lesson from this has got to be: don't leave your chemists behind," said Janda.
Funding for the research, published in a paper titled "Pharmacophore Reassignment for Induction of the Immunosurveillant TRAIL" (DOI: 10.1002/anie.201), was provided by The Skaggs Institute for Chemical Biology and TSRI. For more information on the paper, see http://onlinelibrary.